Retatrutide

Our Retatrutide Metabolic Optimization Program utilizes a cutting-edge triple receptor agonist to achieve profound weight loss and superior glycemic control. This once-weekly injectable therapy works by targeting GLP-1, GIP, and glucagon receptors, offering a multi-faceted approach to improve metabolic health. Patients can expect substantial reductions in body weight, enhanced blood sugar regulation, and benefits across various metabolic conditions like liver steatosis and diabetic kidney disease.

Quick answer

Pioneering Retatrutide therapy offers significant weight loss and comprehensive metabolic health improvements for obesity and Type 2 Diabetes.

Options

Pick what fits

Benefits

What to expect

  • Significant Body Weight Reduction
  • Improved Glycemic Control (HbA1c Reduction)
  • Reduction in Liver Steatosis
  • Relief of Knee Osteoarthritis Pain in Obese Patients

Ideal for

Who this helps

Adults with Obesity (BMI >30 kg/m²)Adults with Type 2 Diabetes Mellitus seeking improved glycemic control and weight managementIndividuals with metabolic syndrome components seeking comprehensive metabolic improvement

How it works

The procedure

01
Retatrutide acts as a triple receptor agonist, activating GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and glucagon receptors.
02
Activation of GLP-1 and GIP receptors enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite.
03
Glucagon receptor agonism may increase energy expenditure and fat metabolism, contributing to significant weight loss.
04
The combined effect leads to profound reductions in body weight, improved glycemic control, and beneficial metabolic adaptations across multiple organ systems.

Conditions

Treats

FAQ

Frequently asked

More services

You might also like